HomeSample Page

Sample Page Title

Knowledge on the viral rebound and security of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are restricted. The research prospectively adopted 4 LTx recipients. Medical traits, viral RNA dynamic in throat swabs, and tacrolimus blood focus have been monitored often. All 4 LTx recipients, aged 35–74 years, weren’t vaccinated in opposition to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They bought coronavirus illness 2019 (COVID-19) after a couple of week of admission in the course of the period of Omicron.

All circumstances obtained nirmatrelvir/ritonavir (NM/r) inside two days of an infection, and the relative viral RNA copies dropped rapidly. Viral load rebound was noticed in all 4 circumstances after discontinuation of the primary 5 days of NM/r remedy. Three of them obtained one other 5-days antiviral remedy with NM/r. The length of constructive viral PCR testing was 25-28 days. None of them progressed into extreme or vital COVID-19. Tacrolimus was stopped 12 h earlier than NM/r and held in the course of the 5-day course of antiviral remedy. Blood focus of tacrolimus have been maintained at a baseline degree throughout these 5 days.

Tacrolimus was re‐initiated at its baseline each day dose 3-4 days after NM/r remedy. Nonetheless, in the course of the second spherical of antiviral remedy with NM/r, the focus of tacrolimus fluctuated wildly. In conclusion, the 5-day course of NM/r remedy was not enough for LTx recipients and the viral rebound was widespread. Extra information are wanted to make clear whether or not LTx recipients with SARS-CoV-2 viral rebound may benefit from extra remedy with NM/r.


Journal reference:

Li, H., et al. (2023). Viral rebound and security of nirmatrelvir/ritonavir for lung-transplant recipients contaminated with SARS-CoV-2. Biosafety and Well being.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments